ES3042447T3 - Salt and crystal form of an azetidinyl substituted isoquinline acting as epidermal growth factor receptor inhibitor for the treatment of cancer - Google Patents
Salt and crystal form of an azetidinyl substituted isoquinline acting as epidermal growth factor receptor inhibitor for the treatment of cancerInfo
- Publication number
- ES3042447T3 ES3042447T3 ES22744048T ES22744048T ES3042447T3 ES 3042447 T3 ES3042447 T3 ES 3042447T3 ES 22744048 T ES22744048 T ES 22744048T ES 22744048 T ES22744048 T ES 22744048T ES 3042447 T3 ES3042447 T3 ES 3042447T3
- Authority
- ES
- Spain
- Prior art keywords
- compound
- egfr
- salt
- cancer
- disclosure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/10—Succinic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/12—Glutaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/15—Fumaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163214089P | 2021-06-23 | 2021-06-23 | |
| PCT/US2022/034550 WO2022271846A1 (en) | 2021-06-23 | 2022-06-22 | Salt and crystal forms of an epidermal growth factor receptor inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES3042447T3 true ES3042447T3 (en) | 2025-11-20 |
Family
ID=82608408
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES22744048T Active ES3042447T3 (en) | 2021-06-23 | 2022-06-22 | Salt and crystal form of an azetidinyl substituted isoquinline acting as epidermal growth factor receptor inhibitor for the treatment of cancer |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240293404A1 (https=) |
| EP (1) | EP4359400B1 (https=) |
| JP (1) | JP2024523506A (https=) |
| CN (1) | CN117836287A (https=) |
| CA (1) | CA3223859A1 (https=) |
| ES (1) | ES3042447T3 (https=) |
| IL (1) | IL309469A (https=) |
| TW (1) | TW202317543A (https=) |
| WO (1) | WO2022271846A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202309022A (zh) | 2021-04-13 | 2023-03-01 | 美商努法倫特公司 | 用於治療具egfr突變之癌症之胺基取代雜環 |
| EP4358942A1 (en) * | 2021-06-23 | 2024-05-01 | Blueprint Medicines Corporation | Pharmaceutical compositions of an epidermal growth factor receptor inhibitor |
| CN116554150B (zh) * | 2022-12-30 | 2025-12-19 | 苏州浦合医药科技有限公司 | 第四代egfr抑制剂 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI726968B (zh) * | 2016-01-07 | 2021-05-11 | 開曼群島商Ｃｓ醫藥技術公司 | Egfr酪胺酸激酶之臨床重要突變體之選擇性抑制劑 |
| MX2022007969A (es) * | 2019-12-23 | 2022-12-13 | Blueprint Medicines Corp | Inhibidores de egfr. |
| US20240058340A1 (en) * | 2020-09-21 | 2024-02-22 | The Regents Of The University Of California | Compositions and methods for treating cancer |
| EP4358942A1 (en) * | 2021-06-23 | 2024-05-01 | Blueprint Medicines Corporation | Pharmaceutical compositions of an epidermal growth factor receptor inhibitor |
| AR126196A1 (es) * | 2021-06-23 | 2023-09-27 | Blueprint Medicines Corp | Proceso para preparar inhibidores de egfr |
-
2022
- 2022-06-22 JP JP2023579154A patent/JP2024523506A/ja active Pending
- 2022-06-22 CN CN202280057121.2A patent/CN117836287A/zh active Pending
- 2022-06-22 WO PCT/US2022/034550 patent/WO2022271846A1/en not_active Ceased
- 2022-06-22 TW TW111123214A patent/TW202317543A/zh unknown
- 2022-06-22 ES ES22744048T patent/ES3042447T3/es active Active
- 2022-06-22 IL IL309469A patent/IL309469A/en unknown
- 2022-06-22 EP EP22744048.4A patent/EP4359400B1/en active Active
- 2022-06-22 US US18/573,222 patent/US20240293404A1/en active Pending
- 2022-06-22 CA CA3223859A patent/CA3223859A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3223859A1 (en) | 2022-12-29 |
| WO2022271846A1 (en) | 2022-12-29 |
| JP2024523506A (ja) | 2024-06-28 |
| EP4359400B1 (en) | 2025-07-02 |
| EP4359400A1 (en) | 2024-05-01 |
| IL309469A (en) | 2024-02-01 |
| US20240293404A1 (en) | 2024-09-05 |
| TW202317543A (zh) | 2023-05-01 |
| CN117836287A (zh) | 2024-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES3042447T3 (en) | Salt and crystal form of an azetidinyl substituted isoquinline acting as epidermal growth factor receptor inhibitor for the treatment of cancer | |
| ES2928169T3 (es) | Derivados de 4-(3H-indol-5-il)-N-(piridin-2-il)pirimidin-2-amina como inhibidores de proteína cinasa, y método de preparación y uso médico de los mismos | |
| WO2021218110A1 (zh) | 一类苯并噻唑基联芳基类化合物、制备方法和用途 | |
| ES2966512T3 (es) | Formas cristalinas de (S)-1-(4-fluorofenil)-1-(2-(4-(6-(1-metil-1H-pirazol-4-il)pirrolo[2,1-f][1,2,4]triazin-4-il)piperazinil)-pirimidin-5-il)etan-1-amina y métodos de elaboración | |
| WO2020253860A1 (zh) | 芳基磷氧化物类衍生物抑制剂、其制备方法和应用 | |
| ES2956943T3 (es) | Forma cristalina de AZD9291 deuterado, procedimiento de preparación para la misma y uso de la misma | |
| CN118725012A (zh) | 可诱导kras蛋白质降解的化合物及其制备方法和用途 | |
| ES3054794T3 (en) | 4-aminoquinazoline compound | |
| BR112020005463A2 (pt) | formas cristalinas | |
| KR101668931B1 (ko) | 항종양제의 효과 증강제 | |
| BR112021005513A2 (pt) | derivados de quinazolina como inibidor de tirosina quinase, composições, métodos de fabricação e uso dos mesmos | |
| AU2019218186B2 (en) | Urea-substituted aromatic ring-linked dioxinoquinoline compounds, preparation method and uses thereof | |
| WO2020114388A1 (zh) | 取代的吡唑并[1,5-a]吡啶化合物及包含该化合物的组合物及其用途 | |
| WO2022271630A1 (en) | Egfr inhibitors | |
| CN113387962A (zh) | 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用 | |
| BR112021005750A2 (pt) | inibidor de fgfr4 e uso do mesmo | |
| ES2981015T3 (es) | Forma cristalina de compuesto que suprime la actividad de la proteína quinasa y aplicación de la misma | |
| WO2021121390A1 (zh) | 杂环化合物及其药物组合物、制备方法、中间体和应用 | |
| WO2024188086A1 (zh) | 芳香酰胺类衍生物及其制备方法和用途 | |
| US20240308981A1 (en) | Heterocyclic egfr inhibitors for use in the treatment of cancer | |
| CN117693517A (zh) | 用于靶向治疗肾癌的新型化合物和组合物 | |
| WO2021036814A1 (zh) | 吡唑衍生物及其用途 | |
| HK40104230A (zh) | 表皮生长因子受体抑制剂的盐和晶体形式 | |
| US20200399284A1 (en) | Urea-substituted aromatic ring-linked dioxinoquinoline compounds, preparation method and uses thereof | |
| WO2026026870A1 (zh) | 环状内酯化合物及其医药用途 |